Use of thiazolidinediones and fracture risk

Archives of Internal Medicine

Volumn 168, Issue 8, 2008, Pages 820-825

  Meier, Christian ^a   Kraenzlin, Marius E ^a   Bodmer, Michael ^a   Jick, Susan S ^b,c   Jick, Hershel ^b,c   Meier, Christoph R ^a,b,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; AGE; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CASE CONTROL STUDY; COMORBIDITY; DRUG USE; FEMALE; FRACTURE; FRAGILITY FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; SEX RATIO; SMOKING; STATISTICAL ANALYSIS; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; RISK ASSESSMENT; THIAZOLIDINEDIONES;

EID: 42949088130     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.8.820     Document Type: Article

References (34)

1. Isaia GC, Ardissone P, Di Stefano M, et al. Bone metabolism in type 2 diabetes mellitus. Acta Diabetol. 1999;36(1-2):35-38.
2. Barrett-Connor E, Holbrook TL. Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus. JAMA. 1992;268(23):3333-3337.
3. van Daele PL, Stolk RP, Burger H, et al. Bone density in non-insulin-dependent diabetes mellitus: the Rotterdam Study. Ann Intern Med. 1995;122(6):409-414.
4. Schwartz AV, Hillier TA, Sellmeyer DE, et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care. 2002;25(10):1749-1754.
5. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab. 2006;91(9):3404-3410.
6. Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care. 2001;24(7):1192-1197.
7. Taylor BC, Schreiner PJ, Stone KL, et al. Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc. 2004;52(9):1479-1486.
8. Strotmeyer ES, Cauley JA, Schwartz AV, et al. Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: the Health, Aging, and Body Composition Study. J Bone Miner Res. 2004;19(7):1084-1091.
9. Strotmeyer ES, Cauley JA, Schwartz AV, et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the Health, Aging, and Body Composition Study. Arch Intern Med. 2005;165(14):1612-1617.
10. de Liefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int. 2005;16(12):1713-1720.
11. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005;48(7):1292- 1299.
12. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001;86(1):32-38.
13. Yki-Järvinen H. The PROactive study: some answers, many questions. Lancet. 2005;366(9493):1241-1242.
14. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology. 2004;145(1):401-406.
15. Sorocéanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol. 2004;183(1):203-216.
16. Sottile V, Seuwen K, Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARγ agonist BRL49653 (rosiglitazone). Calcif Tissue Int. 2004;75(4):329-337.
17. Akune T, Ohba S, Kamekura S, et al. PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004;113(6):846-855.
18. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 2005;146(3):1226-1235.
19. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006;91(9):3349-3354.
20. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007;92(4):1305-1310.
21. Yaturu S, Bryant B, Jain SK. Thiazolidinediones treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care. 2007;30(6):1574-1576.
22. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443.
23. Short R. Fracture risk is a class effect of glitazones [news]. BMJ. 2007;334(7593):551.
24. Hampton T. Diabetes drugs tied to fractures in women [news]. JAMA. 2007;297(15):1645.
25. García Rodríguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45(5):419-425.
26. Wood L, Martinez C. The general practice research database: role in pharmacovigilance. Drug Saf. 2004;27(12):871-881.
27. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302(6779):766-768.
28. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy. 2003;23(5):686-689.
29. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 2000;283(24):3205-3210.
30. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of β-blockers and risk of fractures. JAMA. 2004;292(11):1326-1332.
31. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383-1389.
32. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology. 2007;148(6):2669-2680.
33. Lecka-Czernik B, Gubrij I, Moerman EJ, et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2. J Cell Biochem. 1999;74(3):357-371.
34. Ton FN, Gunawardene SC, Lee H, Neer RM. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res. 2005;20(3):464-470.